Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 9/20 | 0.67 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.55 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20432085 | 0.87 | SLC9A1 (0.63) | SLC9A1RAB9ANPC1MAPTGLA | |
| SCHEMBL11955094 | 0.82 | SLC9A1 (0.65) | SLC9A1RAB9ANPC1MAPTGLA | |
| SCHEMBL283896 | 0.80 | SLC9A1 (1.00) | SLC9A1RAB9ANPC1MAPTGLA | |
| SCHEMBL14796568 | 0.80 | SLC9A1 (0.79) | SLC9A1RAB9ANPC1MAPTGLA | |
| Hydrochloric Acid SCHEMBL28971613 | 0.78 | SLC9A1 (0.65) | SLC9A1RAB9ANPC1MAPTGLA | |
| SCHEMBL1834794 | 0.77 | SLC9A1 (1.00) | SLC9A1RAB9ANPC1MAPTGLA | |
| SCHEMBL4222242 | 0.77 | SLC9A1 (0.68) | SLC9A1RAB9ANPC1MAPTGLA | |
| SCHEMBL18977498 | 0.77 | SLC9A1 (0.68) | SLC9A1RAB9ANPC1MAPTGLA | |
| SCHEMBL731716 | 0.77 | SLC9A1 (0.68) | SLC9A1RAB9ANPC1MAPTGLA | |
| SCHEMBL9736987 | 0.77 | SLC9A1 (0.68) | SLC9A1RAB9ANPC1MAPTGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067656-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-02-29 | — | — | US | disclosed |
| US-10023588-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-17 | — | — | US | disclosed |
| US-9688702-B2 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | ARES TRADING (CH) | 2017-06-27 | — | — | US | disclosed |
| US-9688702-B2 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | ARES TRADING (CH) | 2017-06-27 | — | — | US | disclosed |
| US-20140364396-A1 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | ARES TRADING SA (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140364396-A1 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | ARES TRADING SA (CH) | 2014-12-11 | — | — | US | disclosed |
| WO-2011119559-A1 | NOVEL SPIRO IMIDAZOLONES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | SCHERING CORPORATION (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023588-B2 | Compositions and methods for treating cancer | KRAS, HRAS, NRAS | SLC9A1 4096/4885RAB9A 83/4885NPC1 2113/4885 |
| US-20240067656-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | SLC9A1 4096/4885RAB9A 83/4885NPC1 2113/4885 |
| US-20140364396-A1 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | PSMB7, PSMA7, PSMB1 | SLC9A1 2122/4885RAB9A 1304/4885NPC1 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.